-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 22nd, a press conference on "Common Requirements for Stem Cells" hosted by the China Cell Biology Stem Cell Biology Branch and hosted by the Institute of Stem Cell and Regeneration Innovation of the Chinese Academy of Sciences was held in Beijing.
according to its proliferation, differentiation ability and functional type, stem cells can be divided into several types, such as embryonic stem cells, hematopoietic stem cells, interstitial stem cells, among which interstiturate stem cells are the most widely used in clinical applications, the largest potential for clinical application of stem cell types.
The Chief Scientist of Han's United Biotechnology Co., Ltd. ("Han's Joint Biotechnology Co., Ltd."), the National Engineering Research Center for Cell Products led by Han Zhongchao, a well-known stem cell expert in China, and Tianjin Ansay Cell Genetic Engineering Co., Ltd., wrote the "Human Placental Cord Interstitual Hyperthetic Stem Cell Bank and Its Construction Methods" (Patent No. Three interstitial stem cell technical standards were published in 2011, namely, "Technical Conditions for The Storage of The Self-Contained Stem Cells Of the Cord" (record number Q/12KF 5296-2011), "Technical Conditions for the Public Library of The Inter-Cord Charged Stem Cell Bank" (Record Q/12K297-2011), and "Technical Conditions for Interumbar Charge Duminct Stem Cell Products" (file Q/12K881).
these three technical standards obtained by the Tianjin Quality Standards Bureau issued by the enterprise product implementation standard certificate, by the cell products national engineering research center chief engineer Geng Jie, led the national quality standards of the General Administration of national standards to develop a special research, and finally by the Chinese Society of Biomedical Engineering stem cell engineering branch issued in 2012 implementation.
these stem cell technical standards and norms promulgated and implemented 6 years ago, China's inter-mass stem cell new technology research and development industrialization and standardization speed significantly accelerated, stem cell clinical transformation research is changing rapidly.
applying these stem cell technical standards, Han Zhongchao's team conducted a number of clinical studies and published a series of clinical research papers in international journals.
such as umbilical cord hyperplasia stem cells for the treatment of autoimmune disease systemic sclerosis (Cell Res, 2008; MultScler, 2009), placental interstitument stem cell treatment type 2 diabetes (Front Med, 2011), umbilical cord interstituated stem cell and semi-combined hematopoietic stem cell co-transplanttreatment leukemia (Ann Hetomal, 2013) and regenerative anemia (Cell Res, 2014); Plos One, 2014).
the above results prove the safety and effectiveness of interstitial stem cell products prepared by the application of technical standards set by the National Center.
Han Zhongchao research team has won a number of national and provincial-level scientific and technological awards, including the "Blood Stem Cell Technology and Its Application" project, in 2009 won the second prize of the National Science and Technology Progress Award; First prize of scientific and technological progress award, "cord-to-cord hyperplial stem cell technology and its application" project won the second prize of the 2012 Tianjin Technology Invention Award, "The construction of the cord hematopoietic stem cell bank and related technology research" project won the first prize of the 2003 Tianjin Science and Technology Progress Award.
.